Genticel is vaccinating against Cervical Cancer AFTER Infection

10/06/2016 - 2 minutes

Estonia, our previous destination by the Baltic Sea, was a delightful and a full of potential place to visit.

This week, we are heading down to the relaxing and sunny south of France, more precisely to Toulouse, once the capital of the Visigothic Kingdom and current to the Midi-Pyrénées region, the largest region in metropolitan France.

It is also where Genticel, our Biotech of the Week, is located!


City: Toulouse (France)

Founded: 2001

Related Content

Employees: 33 (as of 11/2015)

Financial Data: €96.26M Market Cap

CEO: Benedikt Timmerman



Genticel is a clinical biotech developing a cervical cancer immunotherapy against the Human papillomavirus (HPV), which causes around 70% of cases of cervical cancer.

Related Content

With its two leading molecules, Genticel is the first company to have established a staged pipeline of HPV therapeutic vaccines for the large female population burdened with this unmet medical need.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

You might also be interested in the following:

Support Us

Become a Member